---
search:
  boost: 3
---

# Bowel Preparations

Bowel Preparations is a subcategory of Gastrointestinal Agents.

## Formulary

### Preferred

| Preferred                                   | Generic Name | Quantity | Time (Days) |
|:--------------------------------------------|:-------------|:--------:|:-----------:|
| Clenpiq                                     |              |          |             |
| Gavilyte-C                                  |              |          |             |
| Gavilyte-G                                  |              |          |             |
| Golytely                                    |              |          |             |
| PEG-3350 and Electrolytes 236-22.7G, 420G   |              |          |             |
| Suprep <sup> BVG (==Process by NDC==)</sup> |              |          |             |

### Non-Preferred

| Non-Preferred                             | Generic Name | Quantity | Time (Days) |
|:------------------------------------------|:-------------|:--------:|:-----------:|
| Moviprep                                  |              |          |             |
| PEG3350-SOD SUL-NACL-KCL-ASB-C 7.5-2.691G |              |          |             |
| Plenvu                                    |              |          |             |
| Suflave                                   |              |          |             |
| SOD SULF-POTASS SULF-MAG SULF Soln        |              |          |             |
| Sutab                                     |              |          |             |

## Authorizations

**Length of Authorizations**: 365 days

**All Authorizations:** Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) OR
    - For any solid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a non-solid oral dosage formulation
- Must have had an inadequate clinical response with at least ^^one preferred^^ drug
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=58){:target="_blank" rel="noopener"}

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=67){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=23){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
